BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breasts
MENLO PARK, Calif., May 9, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the women's health and dermatology markets, will present research showing the link between molecular iodine and lifelong breast health in women.
The study, entitled "Molecular Iodine: the Missing Key to Healthy Aging of the Female Breast," is the only poster presentation on breast health at Vitafoods™ Europe Conference, an international meeting dedicated to ingredients and raw materials for the nutraceutical, functional food and drink and nutricosmetics industries.
"Our review of literature shows that adequate daily supplementation with molecular iodine yields protection against the development of fibrocystic tissue in breasts," said AnnaMarie Daniels, executive vice president of regulatory and clinical affairs, who will present the company's findings at Vitafoods Europe. "Studies have repeatedly shown that taking the right kind of molecular iodine supplements can significantly improve the quality of life for women."
The research, which reviews three studies involving more than 2,200 women, concludes that molecular iodine can help restore normal breast tissue and decrease the symptoms of an ailment known as fibrocystic breast condition (FBC), including breast swelling, pain and tenderness that can interfere with activities of daily life.
FBC affects at least 70 percent of premenopausal women. The condition occurs when repeated hormonal exposure accelerates cell division, often resulting in the formation of cysts, fibrous tissue and chronic inflammation.
BioPharmX has developed a novel and proprietary formulation of molecular iodine that delivers the optimal dose to alleviate FBC symptoms. The product, Violet® iodine, is commercially available in the United States. It is also the subject of a multicenter clinical trial in women with moderate to severe FBC to confirm the safety and expand claims.
Vitafoods screens proposals to present posters at its annual meeting. Event organizers describes the poster presentations as a "showcase [of] excellence in nutritional science, innovation, business and education."
The event is expected to attract 800 exhibitors and more than 15,600 visitors.
MENLO PARK, Calif., May 9, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the women's health and dermatology markets, will present research showing the link between molecular iodine and lifelong breast health in women.
The study, entitled "Molecular Iodine: the Missing Key to Healthy Aging of the Female Breast," is the only poster presentation on breast health at Vitafoods™ Europe Conference, an international meeting dedicated to ingredients and raw materials for the nutraceutical, functional food and drink and nutricosmetics industries.
"Our review of literature shows that adequate daily supplementation with molecular iodine yields protection against the development of fibrocystic tissue in breasts," said AnnaMarie Daniels, executive vice president of regulatory and clinical affairs, who will present the company's findings at Vitafoods Europe. "Studies have repeatedly shown that taking the right kind of molecular iodine supplements can significantly improve the quality of life for women."
The research, which reviews three studies involving more than 2,200 women, concludes that molecular iodine can help restore normal breast tissue and decrease the symptoms of an ailment known as fibrocystic breast condition (FBC), including breast swelling, pain and tenderness that can interfere with activities of daily life.
FBC affects at least 70 percent of premenopausal women. The condition occurs when repeated hormonal exposure accelerates cell division, often resulting in the formation of cysts, fibrous tissue and chronic inflammation.
BioPharmX has developed a novel and proprietary formulation of molecular iodine that delivers the optimal dose to alleviate FBC symptoms. The product, Violet® iodine, is commercially available in the United States. It is also the subject of a multicenter clinical trial in women with moderate to severe FBC to confirm the safety and expand claims.
Vitafoods screens proposals to present posters at its annual meeting. Event organizers describes the poster presentations as a "showcase [of] excellence in nutritional science, innovation, business and education."
The event is expected to attract 800 exhibitors and more than 15,600 visitors.
